Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 361 to 375 of 666 results for kidney or kidneys or renal

  1. Subcutaneous automated low-flow pump implantation for refractory ascites caused by cirrhosis (HTG490)

    Evidence-based recommendations on subcutaneous automated low-flow pump implantation for refractory ascites in adults. This involves inserting a pump under the skin to move excess fluid from the abdomen to the bladder, where it is passed in the urine.

  2. Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)

    Evidence-based recommendations on mogamulizumab (Poteligeo) for previously treated mycosis fungoides and Sézary syndrome in adults.

  3. Tirzepatide for treating type 2 diabetes (TA924)

    Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.

  4. Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

    Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

  5. Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure (HTG599)

    Evidence-based recommendations on percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure in adults. This involves putting a small electronic pressure sensor into the pulmonary artery to measure blood pressure.

  6. Impetigo: antimicrobial prescribing (NG153)

    This guideline sets out an antimicrobial prescribing strategy for adults, young people and children aged 72 hours and over with impetigo. It aims to optimise antibiotic use and reduce antibiotic resistance.

  7. Otitis media (acute): antimicrobial prescribing (NG91)

    This guideline sets out an antimicrobial prescribing strategy for acute otitis media (ear infection). It aims to limit antibiotic use and reduce antimicrobial resistance. Acute otitis media can be caused by viruses or bacteria. It lasts for about a week, and most children get better in 3 days without antibiotics. Serious complications are rare.

  8. Sore throat (acute): antimicrobial prescribing (NG84)

    This guideline sets out an antimicrobial prescribing strategy for acute sore throat. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sore throat is often caused by a virus, lasts for about a week, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.

  9. Pneumonia: diagnosis and management (NG250)

    This guideline covers diagnosing, assessing, and treating community-acquired and hospital-acquired pneumonia, including bacterial pneumonia secondary to COVID-19, in babies over 1 month (corrected gestational age), children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.

  10. Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)

    Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.

  11. Endovascular stent–graft placement in thoracic aortic aneurysms and dissections (HTG76)

    Evidence-based recommendations on endovascular stent–graft placement in thoracic aortic aneurysms and dissections. This involves placing a stent covered in graft material inside the aorta under X-ray guidance.

  12. Cost saving guidance

    with acute or chronic severe sciatica. Cash savings: £2,000 Guideline on renal and ureteric stones: assessment and management (NG118)...

  13. Partial left ventriculectomy (the Batista procedure) (HTG19)

    Evidence-based recommendations on partial left ventriculectomy. This involves reducing the size of a part of the heart so it can pump blood more efficiently.

  14. Ticagrelor for the treatment of acute coronary syndromes (TA236)

    Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes in adults.

  15. Preventive treatment following shockwave lithotripsy:- What is the clinical and cost effectiveness of empirical potassium citrate or bendroflumethiazide as preventive treatment for people with small residual fragments following shockwave lithotripsy for renal and ureteric stones?

    people with small residual fragments following shockwave lithotripsy for renal and ureteric stones? Any explanatory notes(if applicable)...